Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.09. On average, analysts expect Rapport Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Rapport Therapeutics Stock Performance
RAPP traded down $1.33 on Thursday, hitting $8.18. 115,096 shares of the company were exchanged, compared to its average volume of 174,168. The firm has a fifty day simple moving average of $10.12 and a two-hundred day simple moving average of $14.17. Rapport Therapeutics has a 12 month low of $6.43 and a 12 month high of $29.74. The stock has a market capitalization of $298.41 million and a PE ratio of -2.37.
Analysts Set New Price Targets
Several equities analysts recently issued reports on RAPP shares. JMP Securities started coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They set a "market outperform" rating and a $28.00 price target on the stock. Citizens Jmp started coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. Four analysts have rated the stock with a buy rating, According to data from MarketBeat, Rapport Therapeutics has an average rating of "Buy" and a consensus price target of $32.67.
View Our Latest Analysis on RAPP
Insider Transactions at Rapport Therapeutics
In other Rapport Therapeutics news, Director Wendy B. Young acquired 6,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were purchased at an average cost of $10.21 per share, for a total transaction of $61,260.00. Following the transaction, the director now owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Troy A. Ignelzi bought 9,900 shares of the stock in a transaction dated Wednesday, March 12th. The stock was purchased at an average price of $10.10 per share, with a total value of $99,990.00. Following the purchase, the chief financial officer now owns 9,900 shares in the company, valued at $99,990. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Rhumbline Advisers lifted its stake in shares of Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock valued at $144,000 after purchasing an additional 4,109 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC purchased a new position in shares of Rapport Therapeutics in the 1st quarter valued at approximately $2,039,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Rapport Therapeutics by 86.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after purchasing an additional 4,582 shares during the period.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Stories
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.